March 6, 2017 / 8:07 AM / 7 months ago

BRIEF-UCB releases new CIMZIA data in moderate-to-severe plaque psoriasis

March 6 (Reuters) - UCB SA:

* Announced on Saturday that new Cimzia (Certolizumab Pegol) demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis

Source text: bit.ly/2mKFxD3

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below